AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference (English only)
- New data from the API ADAD Study to be presented in AAIC Focused Topic Session
- New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease
- First-time presentation of innovative biomarker-based translational clinical trial design to evaluate ACI-24.060 in sporadic Alzheimer’s disease and in people with Down syndrome
- Additional data from proof-of-concept clinical study of ACI-12589 PET tracer to detect alpha-synuclein in the brains of living patients
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced 10 upcoming presentations that will be delivered at the Alzheimer’s Association International Conference (AAIC) in San Diego, California (United States) and online, July 31 – August 4, 2022.